COPENHAGEN/LONDON (Reuters) – Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast another year of double-digit record sales growth due to its wildly popular Wegovy weight-loss drug.
The Danish company said it expects sales growth this year between 16% and 25%, as demand soars for Wegovy and diabetes drug Ozempic, which contains the same active ingredient.
(Reporting by Jacob Gronholt-Pedersen and Maggie Fick; Editing by Josephine Mason)
Comments